Navigation Links
PRA Participates in Landmark Alzheimer's Prevention Clinical Trial
Date:7/24/2012

RALEIGH, N.C., July 24, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that it is participating in a groundbreaking Alzheimer's disease study that could lead to treatments delaying or even preventing the emergence of symptoms in people destined to develop the disease because of their genetic background. The clinical trial is a collaborative effort involving the Banner Alzheimer's Institute (BAI); Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY); the University of Antioquia in Colombia; and the National Institutes of Health (NIH). 

The trial will include about 300 participants in Colombia, home to a kindred of nearly 5,000 people who share a rare genetic mutation that triggers Alzheimer's symptoms at an early age. A smaller number of individuals in the United States will also participate. The Phase IIa trial will utilize Genentech's investigational drug crenezumab. This humanized monoclonal antibody targets amyloid beta, a protein thought by many scientists to play a key role in the development of the disease.

"This study has the potential to change patients' lives by shifting the research paradigm in Alzheimer's from treatment to early prevention," said Kent Thoelke, PRA's Executive Vice President of Scientific and Medical Affairs. "PRA and its specialty neurosciences group are proud to be involved with this landmark program and to be working with leaders in the field of Alzheimer's research like Banner Alzheimer's Institute and Genentech."

The prevention trial was recently announced by BAI, Genentech and NIH at the unveiling of the National Plan to Address Alzheimer's Disease. The federal plan aims to develop effective treatment and prevention strategies by the year 2025 by increasing research funding, training health professionals and improving public-private partnerships.

About PRA
PRA is transforming clinical trials through our people, innovation and transparency. PRA prov
'/>"/>

SOURCE PRA
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Misonix Participates In Cleveland Spine Review
2. BlackStratus participates in Joint FDA-ISPE CGMP Conference
3. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
4. President Obama Signs Landmark Accessible Prescription Drug Label Bill
5. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
6. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
7. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
8. Berg Pharma launches clinical trial on BPM 31543 for prevention of chemotherapy-induced alopecia (CIA)
9. Joslin Diabetes Center Convenes Leaders in Diabetes Prevention, Treatment, Payment, Education and Research at Diabetes Innovation 2012
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... SAN FRANCISCO , June 2, 2015  Nektar ... Texas MD Anderson Cancer Center today announced a research ... evaluate NKTR-214, a CD122-biased cytokine designed to preferentially stimulate ... cells found naturally in the body.  CD122, which is ... a key signaling receptor that is known to increase ...
(Date:6/2/2015)... , June 2, 2015 Northstar ... first television and multi-media commercial advertisement, which it ... to promote SNORenz®, the company,s top selling product. ... the company,s past success with television advertising. Previous ... but this, more modern version takes an entertainment-oriented ...
(Date:6/2/2015)... und MADRID , ... Mündliche Präsentation (Abstract   10503), vorgestellt ... Clinical Oncology    PharmaMar teilt ... ( Janssen) Daten der multizentrischen Phase-3-Studie ... Verbesserung beim progressionsfreien Überleben (progression-free survival, PFS) ...
Breaking Medicine Technology:Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 3Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 4Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 5Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 6Northstar releases its direct response multi-media ad designed to be used in national television advertising campaigns 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 3PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 4PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 5PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 6
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
(Date:6/2/2015)... 02, 2015 Thermi, formerly ThermiAesthetics, ... has successfully transitioned into its new company headquarters ... the company’s continued rapid worldwide expansion and houses ... over 25 Thermi employees, including those of the ... , “As one of the fastest growing aesthetic ...
(Date:6/2/2015)... 02, 2015 Each year, Cosmetic Executive ... Beauty Awards. This year, the organization’s members – 8,000 ... of the QVC® Beauty Quest Award at the 2015 ... Emulsion (ME) Technology and 2-in-1 approach to skincare differentiated ... the brand’s loyal consumer and professional fan bases, QVC ...
(Date:6/2/2015)... 02, 2015 Atlantic Spine Center ... surgery with three locations in New Jersey, announces the ... The new facility is at 1045 Park Avenue (at ... and appointments can be arranged by calling 1-844-912-2406. ... Atlantic Spine Center, has been a pioneer in the ...
(Date:6/2/2015)... Mt. View, CA (PRWEB) June 02, 2015 ... state mandated vaccination schedule for children to attend public ... Health, Judiciary and Education but bypassed the Appropriations Committee ... Senate floor 25-10 despite contentious hearings. , “We ... with Personal Belief Exemptions (PBEs) more than it will ...
(Date:6/2/2015)... 2015 Specialty Technical Publishers, premier ... risk solutions , and Radar today announced the ... gap-improvement program. , All organizations need to resolve ... Organizations not only assess and treat risks (managing ... this (risk managing) thereby embedding these capabilities within ...
Breaking Medicine News(10 mins):Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4
... of HIV infection than non-smokers, reveals an analysis ... the journal Sexually Transmitted// Infections. ,Cigarette ... than normal chance of contracting other infections generally, ... ,The researchers trawled through 13 academic research ...
... American Dental Association (ADA) reported that serious damage of oral ... This drug harms the ability of chewing.// ,The ... over 12 million Americans have used methamphetamine, also called meth, ... or smoked. Most of the users are of the age ...
... and Hezbollah in Lebanon made a normally tense situation ... Emanuel Hanski, HHMI// international research scholars from Israel, have ... lab to join the military, not knowing when or ... tanks to check up on their research," says Michaeli. ...
... of Medicine researchers have found high rates of hunger ... western North Carolina,// southwestern Virginia and Forsyth County. ... of hunger, there are segments of the N.C. population ... areas of persistent poverty like Appalachia,” said Sara A. ...
... study has indicated that the Human papillomavirus (HPV) could ... Human papillomavirus is// associated with the growth of warts, ... ,Researchers from New York Hospital-Cornell Medical ... had only a 50% chance of conception through the ...
... here Monday in his bid to complete 24 such runs in ... cancer// research. ,"The 'Great World Run' is my greatest ... run 314.4 miles between Sep 7 and Oct 1, and travel ... final run will be at Newcastle upon Tyne in Britain Oct ...
Cached Medicine News:Health News:Methamphetamine causes severe oral health damage 2Health News:Surveys Find Outright Hunger among Latino Immigrants in North Carolina 2Health News:Surveys Find Outright Hunger among Latino Immigrants in North Carolina 3
Biocryl™ Acrylic Foldable Lens....
The STAAR ELASTIMIDE lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
... The Bausch & Lomb UV-Absorbing, Silicone Posterior ... for primary implantation for the visual correction ... age or older in whom the cataractous ... extraction methods. This device is intended to ...
... lenses are manufactured using the ... Perspex CQ UV PMMA material ... and single piece lenses. Unioptic ... both nonphaco and phaco styles. ...
Medicine Products: